Top 5 Stocks to Buy Now
→ Why this tiny stock may move before the SpaceX IPO drops (From Behind the Markets) (Ad)tc pixel Free ASTH Stock Alerts

Astrana Health (ASTH) Financials

Astrana Health logo
$39.95 +0.36 (+0.91%)
As of 10:40 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Astrana Health

Annual Income Statements for Astrana Health

This table shows Astrana Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 3/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -1.80 11 26 11 14 38 69 45 61 43 22
Consolidated Net Income / (Loss)		 -1.35 10 46 60 18 122 46 46 58 50 24
Net Income / (Loss) Continuing Operations		 -1.35 10 46 60 18 122 46 46 58 50 24
Total Pre-Tax Income 		-1.18 19 50 83 26 178 78 87 90 81 40
Total Operating Income		 -0.69 12 35 88 32 81 98 104 85 89 79
Total Gross Profit		 11 51 83 155 94 148 178 199 215 271 342
Total Revenue		 33 306 356 520 561 687 774 1,144 1,387 2,035 3,182
Operating Revenue		 33 282 356 520 561 687 774 1,144 1,387 2,035 3,182
Total Cost of Revenue		 22 255 273 365 466 539 596 945 1,172 1,763 2,840
Operating Cost of Revenue		 22 255 273 361 468 539 596 945 1,172 1,763 2,840
Total Operating Expenses		 12 39 48 66 62 67 80 95 130 182 263
Selling, General & Admin Expense		 11 21 26 43 41 49 62 78 113 154 217
Depreciation Expense		 0.33 18 19 19 18 18 18 18 18 28 46
Total Other Income / (Expense), net		 -0.49 7.15 15 -5.81 -6.58 98 -20 -18 5.23 -8.53 -39
Interest Expense		 1.33 0.06 0.08 0.56 4.73 9.50 5.39 7.92 16 33 50
Interest & Investment Income		 - 5.25 14 -6.87 -4.88 106 -0.54 7.60 20 19 14
Other Income / (Expense), net		 0.84 1.96 1.05 1.62 3.03 1.08 -14 -17 1.54 5.61 -2.86
Income Tax Expense		 0.16 8.82 3.89 22 8.17 56 32 41 32 31 16
Net Income / (Loss) Attributable to Noncontrolling Interest		 0.45 -1.43 20 49 3.56 84 -23 0.57 -2.87 6.78 1.59
Basic Earnings per Share		 ($0.37) $0.46 $1.01 $0.33 $0.41 $1.03 $1.57 $1.00 $1.30 $0.91 $0.46
Weighted Average Basic Shares Outstanding		 4.89M 24.67M 25.53M 32.89M 52.80M 54.59M 55.96M 57.44M 55.42M 56.25M 55.60M
Diluted Earnings per Share		 ($0.37) $0.41 $0.90 $0.29 $0.39 $1.01 $1.52 $0.99 $1.29 $0.90 $0.46
Weighted Average Diluted Shares Outstanding		 4.89M 27.97M 28.66M 37.91M 52.80M 54.59M 55.96M 57.44M 55.42M 56.25M 55.60M
Weighted Average Basic & Diluted Shares Outstanding		 4.89M 5.21M 6.95M 32.80M 52.80M 54.59M 55.96M 57.44M 55.42M 56.25M 55.60M

Quarterly Income Statements for Astrana Health

This table shows Astrana Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2026 6/30/2025 9/30/2025 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 13 22 12 15 19 16 -6.95 14 9.42 0.37 6.00
Consolidated Net Income / (Loss)		 17 28 -0.09 17 22 19 -7.78 13 10 1.08 6.56
Net Income / (Loss) Continuing Operations		 17 28 -0.09 17 22 19 -7.78 13 10 1.08 6.56
Total Pre-Tax Income 		31 38 0.92 24 32 27 -1.90 20 17 5.67 7.51
Total Operating Income		 27 39 -3.87 30 30 28 0.72 29 20 19 18
Total Gross Profit		 55 73 39 74 73 73 50 106 78 97 95
Total Revenue		 348 348 353 404 486 479 665 965 655 956 951
Operating Revenue		 348 348 353 404 486 479 665 965 655 956 951
Total Cost of Revenue		 293 275 314 330 413 405 615 859 577 859 855
Operating Cost of Revenue		 293 275 314 330 413 405 615 859 577 859 855
Total Operating Expenses		 28 34 43 44 43 45 50 77 58 78 77
Selling, General & Admin Expense		 24 29 38 39 36 38 42 62 51 62 60
Depreciation Expense		 4.25 4.31 4.90 5.10 7.44 7.26 8.13 15 6.90 16 16
Total Other Income / (Expense), net		 4.46 -1.07 4.80 -6.14 1.83 -1.61 -2.62 -8.82 -3.52 -14 -11
Interest Expense		 3.63 3.78 5.42 7.59 8.59 8.86 8.07 16 7.38 18 18
Interest & Investment Income		 6.05 1.18 7.07 4.63 4.42 5.13 4.79 5.54 2.72 4.54 5.16
Other Income / (Expense), net		 2.04 1.53 3.15 -3.18 6.00 2.11 0.67 1.75 1.15 -0.36 1.47
Income Tax Expense		 14 10 1.02 7.14 10 7.83 5.88 6.58 6.61 4.59 0.94
Net Income / (Loss) Attributable to Noncontrolling Interest		 4.31 5.91 -12 2.03 2.70 2.89 -0.83 -1.31 0.79 0.70 0.56
Basic Earnings per Share		 $0.28 $0.47 $0.27 $0.31 $0.40 $0.34 ($0.14) $0.30 $0.19 $0.01 $0.12
Weighted Average Basic Shares Outstanding		 57.56M 58.28M 55.42M 56.03M 56.21M 56.25M 56.25M 55.72M 56.06M 56.29M 55.60M
Diluted Earnings per Share		 $0.28 $0.47 $0.26 $0.31 $0.40 $0.33 ($0.14) $0.29 $0.19 $0.01 $0.12
Weighted Average Diluted Shares Outstanding		 57.56M 58.28M 55.42M 56.03M 56.21M 56.25M 56.25M 55.72M 56.06M 56.29M 55.60M
Weighted Average Basic & Diluted Shares Outstanding		 57.56M 58.28M 55.42M 56.03M 56.21M 56.25M 56.25M 55.72M 56.06M 56.29M 55.60M

Annual Cash Flow Statements for Astrana Health

This table details how cash moves in and out of Astrana Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 3/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -1.82 -4.19 64 -11 -3.63 90 39 55 6.13 -5.05 145
Net Cash From Operating Activities		 -0.27 22 52 25 14 46 70 82 68 52 115
Net Cash From Continuing Operating Activities		 -0.27 22 52 25 14 46 70 82 68 52 115
Net Income / (Loss) Continuing Operations		 -1.35 10 46 60 18 122 46 46 58 50 24
Consolidated Net Income / (Loss)		 -1.35 10 46 60 18 122 46 46 58 50 24
Depreciation Expense		 0.33 18 19 19 18 18 18 18 18 28 46
Amortization Expense		 0.52 - - 0.00 0.47 1.35 1.08 0.94 1.06 1.83 4.05
Non-Cash Adjustments To Reconcile Net Income		 0.50 0.99 -6.49 -4.18 9.31 -100 31 38 27 37 43
Changes in Operating Assets and Liabilities, net		 -0.28 -7.21 -6.57 -50 -32 4.08 -25 -20 -36 -64 -2.22
Net Cash From Investing Activities		 -3.20 -8.96 27 -25 -181 95 17 -7.11 -66 -192 -539
Net Cash From Continuing Investing Activities		 -3.20 -8.96 27 -25 -181 95 17 -7.11 -66 -192 -539
Purchase of Property, Plant & Equipment		 -0.04 -3.31 -2.08 -1.17 -1.04 -1.16 -19 -23 -29 -8.03 -10
Acquisitions		 -3.36 -2.44 0.00 -17 -53 -21 -16 -16 -6.84 -152 -549
Purchase of Investments		 - -5.21 -10 -7.91 -127 -1.94 -28 -1.85 -26 -30 -1.71
Divestitures		 0.00 0.00 37 0.00 0.00 53 6.38 - 0.00 0.00 15
Other Investing Activities, net		 -0.24 0.00 0.23 - 0.00 0.00 5.93 1.96 -3.68 -2.23 6.32
Net Cash From Financing Activities		 1.66 -17 -15 -11 163 -52 -48 -20 3.42 135 569
Net Cash From Continuing Financing Activities		 1.66 -17 -15 -11 163 -52 -48 -20 3.42 135 569
Repayment of Debt		 -1.47 -2.26 -9.10 -0.59 -55 -9.61 -239 -4.43 -208 -18 -512
Repurchase of Common Equity		 - -0.52 -3.18 -5.05 -13 -0.54 -6.47 -9.25 -10 -0.94 -15
Payment of Dividends		 -0.60 -26 -10 -18 -62 -52 -33 -19 -62 -4.04 -7.89
Issuance of Debt		 3.00 0.00 5.00 8.00 290 0.00 181 3.60 285 172 1,119
Other Financing Activities, net		 -0.00 0.26 0.59 4.00 3.12 11 9.06 8.63 -1.00 -14 -14
Cash Interest Paid		 0.77 0.06 0.05 0.46 4.26 8.51 4.16 6.67 14 30 46
Cash Income Taxes Paid		 0.03 29 24 24 20 62 37 47 57 44 0.00

Quarterly Cash Flow Statements for Astrana Health

This table details how cash moves in and out of Astrana Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Change in Cash & Equivalents		 20 -20 20 41 -9.49 23 -60 -30 81 124 -30
Net Cash From Operating Activities		 26 15 19 5.98 23 34 -11 17 91 9.96 -2.89
Net Cash From Continuing Operating Activities		 26 15 19 5.98 23 34 -11 17 91 9.96 -2.89
Net Income / (Loss) Continuing Operations		 17 28 -0.09 17 22 19 -7.78 6.22 10 1.08 6.56
Consolidated Net Income / (Loss)		 17 28 -0.09 17 22 19 -7.78 6.22 10 1.08 6.56
Depreciation Expense		 4.25 4.31 4.90 5.10 7.44 7.26 8.13 6.85 6.90 16 16
Amortization Expense		 0.24 0.24 0.35 0.46 0.46 0.46 0.45 0.69 1.05 1.15 1.16
Non-Cash Adjustments To Reconcile Net Income		 4.46 5.98 5.22 14 -30 7.62 11 1.82 68 -4.91 -30
Changes in Operating Assets and Liabilities, net		 -0.63 -23 8.92 -30 23 -0.34 -23 1.05 5.00 -2.96 2.71
Net Cash From Investing Activities		 -5.19 -35 -11 -71 -80 -8.11 -33 -2.39 -1.08 -534 -1.06
Net Cash From Continuing Investing Activities		 -5.19 -35 -11 -71 -80 -8.11 -33 -2.39 -1.08 -534 -1.06
Purchase of Property, Plant & Equipment		 -11 -4.11 -7.06 -0.37 -2.84 -2.30 -2.53 -3.07 -1.42 -2.55 -3.06
Acquisitions		 0.35 -5.02 -1.84 -51 -70 -0.91 -31 0.00 - -549 -0.05
Other Investing Activities, net		 8.82 -0.70 -1.00 0.01 -2.31 0.10 - 0.68 1.47 2.19 2.06
Net Cash From Financing Activities		 -0.96 -0.51 12 106 47 -3.19 -15 -44 -8.64 648 -26
Net Cash From Continuing Financing Activities		 -0.96 -0.51 12 106 47 -3.19 -15 -44 -8.64 648 -26
Repayment of Debt		 -0.31 -0.35 -208 -3.68 -7.56 -4.14 -3.89 -447 -7.90 -50 -8.75
Payment of Dividends		 -0.72 -1.42 -60 0.03 -1.93 -0.22 -1.94 -5.46 -0.75 -0.10 -1.56
Other Financing Activities, net		 -0.05 - -0.73 0.00 -3.58 -0.39 -9.22 -4.05 -1.00 -8.79 -0.61
Cash Interest Paid		 3.27 3.41 4.58 6.43 8.18 8.58 7.23 7.36 6.18 17 16
Cash Income Taxes Paid		 - - 49 0.19 36 2.53 5.67 4.34 0.39 - -4.73

Annual Balance Sheets for Astrana Health

This table presents Astrana Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 3/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 15 350 491 513 729 817 867 966 933 1,355 2,219
Total Current Assets		 9.85 81 144 173 329 339 404 428 462 638 863
Cash & Equivalents		 5.01 55 100 107 103 193 233 288 294 288 429
Short-Term Investments		 - 1.05 1.14 1.13 117 68 53 5.57 2.50 0.00 0.00
Note & Lease Receivable		 - - - 0.00 23 0.00 4.00 3.12 - 0.00 4.93
Accounts Receivable		 4.05 22 20 57 76 61 90 117 137 305 401
Prepaid Expenses		 0.79 1.85 5.14 7.39 10 17 19 15 17 25 26
Current Deferred & Refundable Income Taxes		 - - - - - - - 0.00 11 19 1.80
Plant, Property, & Equipment, net		 0.58 10 14 13 12 30 53 109 7.17 14 57
Total Noncurrent Assets		 4.56 258 333 327 388 449 410 430 465 702 1,298
Long-Term Investments		 - 35 22 35 29 80 43 43 32 48 26
Noncurrent Note & Lease Receivables		 - 5.20 15 18 0.00 4.63 0.57 0.00 26 51 49
Goodwill		 2.17 103 190 186 239 239 246 269 279 419 865
Intangible Assets		 1.38 108 104 87 103 87 83 77 72 118 271
Noncurrent Deferred & Refundable Income Taxes		 - - - - - - 16 16 16 16 26
Other Noncurrent Operating Assets		 0.75 6.94 2.38 1.95 17 38 21 25 40 49 61
Total Liabilities & Shareholders' Equity		 15 350 491 513 729 817 867 966 933 1,355 2,219
Total Liabilities		 16 100 154 106 368 372 357 408 523 841 1,660
Total Current Liabilities		 5.97 51 110 72 105 115 115 149 219 366 615
Short-Term Debt		 1.04 0.10 0.61 0.04 9.50 11 0.78 0.62 20 9.38 48
Accounts Payable		 3.34 9.13 20 27 29 46 54 58 68 114 199
Current Deferred & Payable Income Tax Liabilities		 - 2.81 3.20 12 4.53 4.22 0.00 4.28 - - 0.00
Other Current Liabilities		 1.59 39 85 34 62 54 59 85 131 242 368
Total Noncurrent Liabilities		 10 49 45 34 262 257 242 259 304 475 1,045
Long-Term Debt		 7.69 - - 0.00 232 230 183 203 259 425 991
Noncurrent Deferred & Payable Income Tax Liabilities		 0.17 47 25 20 18 11 30 14 4.07 4.56 5.49
Other Noncurrent Operating Liabilities		 2.14 2.00 19 1.19 12 16 29 41 41 45 49
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 0.00 163 172 225 169 114 57 14 -206 -203 -235
Total Equity & Noncontrolling Interests		 -0.99 88 164 182 192 331 454 544 617 717 793
Total Preferred & Common Equity		 -2.82 87 160 181 192 331 448 543 614 713 779
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -2.82 87 160 181 192 331 448 543 614 713 779
Common Stock		 17 88 158 163 160 261 311 360 371 426 471
Retained Earnings		 -19 -0.77 1.73 18 32 70 137 182 243 286 308
Noncontrolling Interest		 1.83 0.38 4.24 1.00 0.79 0.09 5.94 1.75 2.43 4.01 14

Quarterly Balance Sheets for Astrana Health

This table presents Astrana Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2026 6/30/2025 9/30/2025
Total Assets		 943 999 1,027 1,073 1,226 1,252 1,285 2,359 1,442 2,237
Total Current Assets		 444 455 465 476 539 570 597 1,004 729 884
Cash & Equivalents		 184 275 294 274 335 325 348 478 340 462
Short-Term Investments		 33 4.11 3.79 3.02 2.49 2.38 2.35 0.00 2.42 1.22
Note & Lease Receivable		 0.00 0.97 0.97 0.97 - - - 4.66 - 5.91
Accounts Receivable		 202 153 151 184 184 203 210 495 357 391
Prepaid Expenses		 12 22 15 14 17 17 21 26 22 23
Current Deferred & Refundable Income Taxes		 12 0.00 - - 0.00 22 16 0.00 7.89 0.00
Plant, Property, & Equipment, net		 104 113 124 129 7.99 10 12 60 18 56
Total Noncurrent Assets		 396 431 438 468 679 672 676 1,295 695 1,297
Long-Term Investments		 40 44 49 47 42 42 44 27 47 27
Noncurrent Note & Lease Receivables		 2.64 - - 25 47 49 55 49 48 48
Goodwill		 257 269 274 276 410 410 410 875 417 863
Intangible Assets		 73 78 74 74 120 116 109 257 106 285
Noncurrent Deferred & Refundable Income Taxes		 - 16 16 16 16 16 16 26 16 16
Other Noncurrent Operating Assets		 22 24 25 30 44 39 43 61 61 57
Total Liabilities & Shareholders' Equity		 943 999 1,027 1,073 1,226 1,252 1,285 2,359 1,442 2,237
Total Liabilities		 390 434 444 458 774 774 778 1,781 904 1,682
Total Current Liabilities		 156 173 186 203 355 310 313 745 460 630
Short-Term Debt		 3.16 0.62 2.63 2.99 21 17 15 48 13 48
Accounts Payable		 54 58 59 59 154 103 101 225 124 214
Current Deferred & Payable Income Tax Liabilities		 0.00 11 20 30 5.52 - - 2.51 - 4.92
Other Current Liabilities		 99 102 104 110 174 189 196 470 323 363
Total Noncurrent Liabilities		 234 260 258 255 419 464 465 1,036 445 1,053
Long-Term Debt		 199 205 205 206 368 425 423 980 401 1,002
Noncurrent Deferred & Payable Income Tax Liabilities		 4.70 14 12 12 3.76 3.25 2.86 7.40 2.59 4.43
Other Noncurrent Operating Liabilities		 30 40 39 36 45 36 39 49 41 46
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 40 14 14 18 -206 -204 -203 -238 -234 -234
Total Equity & Noncontrolling Interests		 514 551 570 598 658 683 710 815 772 789
Total Preferred & Common Equity		 510 548 566 594 653 679 705 800 765 776
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 510 548 566 594 653 679 705 800 765 776
Common Stock		 315 353 357 363 396 402 411 478 463 473
Retained Earnings		 195 196 209 231 258 277 293 323 302 302
Noncontrolling Interest		 3.07 2.71 3.74 4.00 4.49 4.13 5.00 15 6.07 14

Annual Metrics And Ratios for Astrana Health

This table displays calculated financial ratios and metrics derived from Astrana Health's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 3/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - - - - - 56,288,415.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 56,288,415.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 0.40
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -0.49 6.22 32 65 22 55 58 55 54 55 48
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - 7.36% 6.09% 4.79% 2.61%
Earnings before Interest and Taxes (EBIT)		 0.14 27 36 90 35 82 84 87 86 95 76
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 1.00 32 55 109 54 101 102 105 105 125 125
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -5.48 -298 155 -16 -55 64 43 -12 120 -194 -479
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 2.46 319 197 277 354 345 360 427 361 610 1,139
Increase / (Decrease) in Invested Capital		 4.99 634 -123 80 77 -8.68 15 67 -66 249 527
Book Value per Share		 ($0.06) $29.28 $26.51 $5.30 $5.49 $6.10 $8.07 $9.57 $10.54 $12.67 $13.84
Tangible Book Value per Share		 ($0.13) ($20.87) ($22.12) ($2.70) ($4.30) $0.09 $2.14 $3.47 $4.53 $3.12 ($6.34)
Total Capital		 7.74 501 338 407 603 686 694 763 689 949 1,597
Total Debt		 8.73 0.29 1.23 0.56 242 241 184 204 278 435 1,039
Total Long-Term Debt		 7.69 0.00 0.62 0.52 232 230 183 203 259 425 991
Net Debt		 3.72 -100 -140 -143 -7.45 -100 -145 -132 -50 96 581
Capital Expenditures (CapEx)		 0.04 6.61 2.08 1.17 1.04 1.11 19 23 29 8.03 10
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.09 -28 -84 -7.14 13 -27 4.01 -13 -34 -8.57 -134
Debt-free Net Working Capital (DFNWC)		 4.92 61 35 101 233 234 291 280 262 282 296
Net Working Capital (NWC)		 3.89 61 35 101 224 224 290 280 243 273 248
Net Nonoperating Expense (NNE)		 0.86 -0.72 -13 4.23 4.50 -67 12 9.32 -3.36 5.27 24
Net Nonoperating Obligations (NNO)		 3.45 -100 -140 -130 -7.18 -100 -151 -132 -49 96 581
Total Depreciation and Amortization (D&A)		 0.86 36 19 19 19 20 19 18 19 30 50
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($1.33) $0.00 $0.33 $0.41 $1.04 $1.69 $0.00 $1.30 $0.91 $0.46
Adjusted Weighted Average Basic Shares Outstanding		 0.00 30.42M 0.00 32.89M 34.71M 36.53M 55.96M 0.00 55.42M 56.25M 55.60M
Adjusted Diluted Earnings per Share		 $0.00 ($1.38) $0.00 $0.29 $0.39 $1.01 $1.63 $0.00 $1.29 $0.90 $0.46
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 5.75M 0.00 37.91M 36.40M 37.45M 55.96M 0.00 55.42M 56.25M 55.60M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($1.79) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 10.43M 0.00 35.80M 52.80M 54.59M 55.96M 0.00 55.42M 56.25M 55.60M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.49 6.39 35 67 24 55 58 55 54 55 48
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for Astrana Health

This table displays calculated financial ratios and metrics derived from Astrana Health's official financial filings.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
DEI Shares Outstanding		 - - - - - - - - - - 56,288,415.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 56,288,415.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 0.11
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 15 29 0.39 21 21 20 0.50 13 12 3.65 16
Return On Investment Capital (ROIC_SIMPLE)		 - - 0.04% - - - 0.04% 1.14% 1.04% 0.20% 0.88%
Earnings before Interest and Taxes (EBIT)		 29 41 -0.72 27 36 31 1.39 15 21 19 20
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 34 45 4.53 33 44 38 9.97 23 29 36 37
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -22 27 66 7.40 -85 -31 -249 -150 1.79 -558 -511
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 446 501 361 464 551 552 610 627 562 1,114 1,139
Increase / (Decrease) in Invested Capital		 37 2.15 -66 14 105 51 249 163 11 562 527
Book Value per Share		 $9.84 $10.32 $10.54 $11.79 $12.12 $12.53 $12.67 $13.25 $13.65 $13.83 $13.84
Tangible Book Value per Share		 $3.78 $4.24 $4.53 $2.23 $2.73 $3.31 $3.12 $3.86 $4.33 ($6.65) ($6.34)
Total Capital		 792 825 689 843 921 945 949 934 952 1,605 1,597
Total Debt		 209 209 278 390 442 438 435 416 414 1,050 1,039
Total Long-Term Debt		 206 206 259 369 425 423 425 404 401 1,002 991
Net Debt		 -138 -115 -50 11 72 44 96 109 24 559 581
Capital Expenditures (CapEx)		 11 4.11 7.06 0.37 0.00 0.00 2.53 3.07 1.42 2.55 3.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -16 -0.70 -34 -133 -50 -51 -8.57 3.59 -60 -162 -134
Debt-free Net Working Capital (DFNWC)		 282 276 262 204 278 299 282 265 282 302 296
Net Working Capital (NWC)		 279 273 243 184 261 284 273 252 269 254 248
Net Nonoperating Expense (NNE)		 -2.48 0.79 0.49 4.31 -1.26 1.14 8.28 7.11 2.13 2.57 9.52
Net Nonoperating Obligations (NNO)		 -137 -114 -49 11 73 45 96 109 24 559 581
Total Depreciation and Amortization (D&A)		 4.49 4.54 5.25 5.55 7.44 7.26 8.58 7.54 7.95 17 18
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.28 $0.47 $0.27 $0.31 $0.40 $0.34 ($0.14) $0.14 $0.19 $0.01 $0.12
Adjusted Weighted Average Basic Shares Outstanding		 57.56M 46.55M 55.42M 56.03M 56.21M 56.25M 56.25M 56.06M 56.06M 56.29M 55.60M
Adjusted Diluted Earnings per Share		 $0.28 $0.47 $0.26 $0.31 $0.40 $0.33 ($0.14) $0.14 $0.19 $0.01 $0.12
Adjusted Weighted Average Diluted Shares Outstanding		 57.56M 46.92M 55.42M 56.03M 56.21M 56.25M 56.25M 56.06M 56.06M 56.29M 55.60M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 57.56M 58.28M 55.42M 56.03M 56.21M 56.25M 56.25M 56.06M 56.06M 56.29M 55.60M
Normalized Net Operating Profit after Tax (NOPAT)		 15 29 -2.71 21 21 20 0.50 13 12 13 16
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Financials Breakdown Chart

Key Financial Trends

Astrana Health’s latest results show a sharp improvement in profitability from the prior quarter, but cash flow remains under pressure and the balance sheet has become more leveraged following a major acquisition.

For Q4 2025, Astrana Health posted $950.5 million in revenue, roughly flat versus Q3 2025 and up meaningfully from the prior year’s quarters. The company generated $18.4 million in operating income and $6.6 million in net income from continuing operations, but the quarter also included substantial interest expense and a negative operating cash flow result. Compared with the broader 2024–2025 trend, the business has grown materially, though integration costs, debt, and working-capital swings remain important watch items.

  • Revenue remains elevated versus prior year levels. Q4 2025 revenue of $950.5 million was far above Q4 2024’s $665.2 million and Q1 2024’s $404.4 million, showing the company has scaled significantly over the last year.
  • Profitability improved versus the year-ago quarter. Q4 2025 net income from continuing operations was $6.6 million, a strong turnaround from a $7.8 million loss in Q4 2024.
  • Operating income stayed positive. Q4 2025 operating income of $18.4 million indicates the core business is still generating earnings before interest and taxes.
  • Gross profit dollars remain solid. Q4 2025 gross profit was $95.0 million, reflecting a sizable revenue base despite high cost of revenue.
  • Cash and equivalents increased over the year. Cash and equivalents were $462.2 million at Q3 2025 versus $347.0 million at Q3 2024, giving the company a stronger liquidity cushion.
  • Free cash generation was strong in Q2 and Q3 2025 before the acquisition-heavy Q3 balance sheet shift. Operating cash flow was $90.9 million in Q2 2025 and $10.0 million in Q3 2025, showing the business can generate cash in normal periods.
  • The company is still absorbing acquisition-related impacts. Goodwill rose to $863.3 million at Q3 2025 from $416.9 million at Q2 2025, and intangible assets increased sharply too, suggesting a major deal was integrated into the balance sheet.
  • Share count has been fairly stable in recent quarters. Diluted shares were 55.6 million in Q4 2025 versus 56.3 million in Q3 2025, limiting dilution pressure for now.
  • Operating cash flow turned negative in Q4 2025. The company reported negative $2.9 million in operating cash flow, down from positive $9.96 million in Q3 2025.
  • Debt increased sharply after the acquisition. Long-term debt jumped to $1.00 billion at Q3 2025 from $401.1 million at Q2 2025, while total liabilities rose to $1.68 billion.

One of the biggest developments in 2025 was the balance sheet expansion. At Q2 2025, Astrana Health had $1.44 billion in assets and $904.4 million in liabilities. By Q3 2025, assets had grown to $2.24 billion and liabilities to $1.68 billion. That kind of jump usually reflects a major acquisition, and the cash flow statement confirms it: Q3 2025 included $548.6 million of acquisition spending and $707.3 million of debt issuance to help finance the transaction.

The earnings trend is more mixed. Revenue has climbed steadily since 2023, but margins have not always kept pace. In Q1 2025, the company earned $28.5 million of operating income on $965.1 million of revenue, but by Q4 2025 operating income was only $18.4 million on slightly lower revenue. That suggests integration and financing costs may be weighing on near-term profitability.

Investors should also pay attention to interest expense. In Q4 2025, interest expense was $17.5 million versus only $5.2 million of interest income, which helped push total other income/expense to a negative $10.9 million. With debt now much higher, interest costs could continue to pressure bottom-line earnings.

Bottom line: Astrana Health has grown quickly and is still profitable, but the latest quarter shows that leverage and acquisition-related integration are now central to the investment case. If management can convert the larger revenue base into stronger operating cash flow and stabilize margins, the recent expansion could prove attractive. If not, the higher debt load may limit flexibility.

06/23/26 10:41 AM ETAI Generated. May Contain Errors.

Astrana Health Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Astrana Health's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Astrana Health's net income appears to be on an upward trend, with a most recent value of $24.08 million in 2025, falling from -$1.35 million in 2015. The previous period was $49.93 million in 2024. Check out Astrana Health's forecast to explore projected trends and price targets.

Astrana Health's total operating income in 2025 was $78.53 million, based on the following breakdown:
  • Total Gross Profit: $341.53 million
  • Total Operating Expenses: $263.01 million

Over the last 10 years, Astrana Health's total revenue changed from $32.99 million in 2015 to $3.18 billion in 2025, a change of 9,544.7%.

Astrana Health's total liabilities were at $1.66 billion at the end of 2025, a 97.5% increase from 2024, and a 10,286.6% increase since 2015.

In the past 10 years, Astrana Health's cash and equivalents has ranged from $5.01 million in 2015 to $429.47 million in 2025, and is currently $429.47 million as of their latest financial filing in 2025.

Over the last 10 years, Astrana Health's book value per share changed from -0.06 in 2015 to 13.84 in 2025, a change of -24,011.2%.


Related Companies

Financial statements for NASDAQ:ASTH last updated on 3/14/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel